Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Eyenovia, Inc. (EYEN)
Last eyenovia, inc. earnings: 3/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=254685&p=irol-irhome
Company Research
Source: GlobeNewswire
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, which is being held October 19-21, in Chicago. The presentation will detail the results of a successful Phase 3 study (CPN-302) of clobetasol propionate suspension 0.05% (APP13007) that led to its approval by the U.S. Food and Drug Administration as a treatment for inflammation and pain following ocular surgery. Eyenovia announced the U.S. launch and commercial availability of clobetasol on September 26, 2024. “We are very pleased to see the results from this successful Phase 3 study of clobetasol presented at this year’s AAO Expo,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “The results demonstrated the magnitude and speed of inflammation and pain relief as soon as four days post-surgery as compared to placebo, with a more rapid improvement in visual acuity and a des
Show less
Read more
Impact Snapshot
Event Time:
EYEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYEN alerts
High impacting Eyenovia, Inc. news events
Weekly update
A roundup of the hottest topics
EYEN
News
- Eyenovia Stock Tumbles on Termination of Phase III Myopia Study [Yahoo! Finance]Yahoo! Finance
- Eyenovia, Inc. (NASDAQ: EYEN) had its "neutral" rating re-affirmed by analysts at LADENBURG THALM/SH SH.MarketBeat
- Eyenovia, Inc. (NASDAQ: EYEN) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $12.00.MarketBeat
- Eyenovia stock plummets following Phase III myopia trial failure [Yahoo! Finance]Yahoo! Finance
- Eyenovia, Inc. (NASDAQ: EYEN) had its "hold" rating re-affirmed by analysts at Brookline Capital Management.MarketBeat
EYEN
Earnings
- 11/12/24 - Beat
EYEN
Sec Filings
- 11/20/24 - Form 8-K
- 11/15/24 - Form 8-K
- 11/14/24 - Form SC
- EYEN's page on the SEC website